Event Brief
GSK buys Nuvalent in $10.6B deal to bolster cancer portfolio
Filed: Jun 09, 2026 at 4:02 AM ET
Summary: GSK agreed to buy U.S.-listed biotech Nuvalent for $10.6 billion, its biggest acquisition in eight years.
WHO: GSK
WHAT: GSK struck a $10.6 billion deal to buy Nuvalent
WHEN: Jun 09, 2026 at 3:37 AM ET
WHERE: Location not specified
WHY: To bolster the cancer portfolio it had previously trimmed
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →